Purine synthesis pathway enzymes and nucleic acids

The purine synthesis pathway enzymes and nucleic acids represent a broad category of therapeutic targets involved in the production and utilization of adenine and guanine nucleotides. This system encompasses the de novo synthesis pathway, which constructs purines from simple precursors like ribose-5-phosphate and amino acids, as well as the salvage pathway, which recycles free bases from degraded genetic material. These processes are fundamental for DNA replication, RNA transcription, and energy transfer via molecules like ATP and GTP, making them vital for the survival of rapidly proliferating cells. Consequently, this target group is a major focus in the treatment of cancer, autoimmune disorders, and viral infections. Pharmacological intervention typically involves enzyme inhibitors that deplete nucleotide pools or antimetabolites that are incorporated into nucleic acids, leading to cell cycle arrest or apoptosis.

Other names

Purine metabolismDe novo purine biosynthesis pathwayPurine salvage pathwayPurine nucleotide synthesis

Inhibition of de novo purine biosynthesis, inhibition of the purine salvage pathway, and antimetabolite-mediated disruption of DNA and RNA synthesis.